Moderna, Novavax, Other Vaccine Makers Retreat Following Resignation of FDA's Vaccines Chief

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

01:17 PM EDT, 03/31/2025 (MT Newswires) -- Shares of several vaccine companies were sharply lower on Monday after the top vaccine official at the US Food and Drug Administration resigned late Friday, blaming the current US Secretary of Health and Human Services for seeking "subservient confirmation of his misinformation and lies."

Dr. Peter Marks had led the FDA's Center for Biologics Evaluation and Research, choosing to step down after 13 years at the agency, which authorizes and monitors vaccine use, among other responsibilities. His expertise, however, ran counter to views and policies advocated by US Health Secretary Robert Kennedy Jr., a noted vaccine skeptic.

In his resignation letter, Marks cited data supporting the efficacy and safety of a two-dose vaccine given for measles, mumps and rubella and rejected assertions it was associated with several adverse side effects. "The vaccine very simply does not cause autism, nor is it associated with encephalitis or death," he said. "It does, however, protect against a potential devastating consequence of prior measles infection, subacute sclerosing panencephalitis, which is an untreatable, relentlessly progressive neurologic disorder."

Shares of Moderna ( MRNA ) , Novavax ( NVAX ) , BioNTech (BNTX) were down 9%, 7.6% and 6.9%, respectively. Pfizer ( PFE ) was off 1% while Inovio Pharmaceuticals ( INO ) was down 6.1% in recent trading.

Price: 28.34, Change: -2.79, Percent Change: -8.95

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.